<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05122559</url>
  </required_header>
  <id_info>
    <org_study_id>P0549747</org_study_id>
    <nct_id>NCT05122559</nct_id>
  </id_info>
  <brief_title>Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis</brief_title>
  <acronym>NACPMS</acronym>
  <official_title>Randomized Controlled Trial of N-acetyl Cysteine as a Neuroprotective Agent in Progressive Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emmanuelle Waubant</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effectiveness of N-acetyl cysteine (NAC) in the treatment of&#xD;
      progressive multiple sclerosis. Half of the patients will receive NAC, while the other half&#xD;
      will receive a placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>15 months</time_frame>
    <description>Safety endpoints include the incidence of adverse events recorded by system, severity, and by relationship to treatment arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of NAC on on progression of brain, thalamic and cervical cord atrophy</measure>
    <time_frame>15 months</time_frame>
    <description>The primary endpoint is brain, thalamic and cord atrophy measured by brain and cervical spine MRI at month 3 and month 15.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical effects of NAC</measure>
    <time_frame>15 months</time_frame>
    <description>Clinical effects in MS as measured by the 9-HPT, 25-foot walk, symbol digit modalities test (SDMT).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Effect of NAC on progression of MS</measure>
    <time_frame>15 months</time_frame>
    <description>Monitoring progression using imaging metrics and changes captured by a wearable multi-sensor device.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">98</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Multiple Sclerosis, Primary Progressive</condition>
  <condition>Multiple Sclerosis, Secondary Progressive</condition>
  <arm_group>
    <arm_group_label>N-acetyl cysteine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>N-acetyl cysteine (NAC) 1200mg t.i.d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 1200mg t.i.d.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetyl cysteine</intervention_name>
    <description>N-acetyl cysteine (NAC) is a Glutathione (GSH) precursor with antioxidant properties which make it relevant for neuroprotection.</description>
    <arm_group_label>N-acetyl cysteine</arm_group_label>
    <other_name>NAC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Lactose Monohydrate, USP (100%), magnesium stearate, silicon dioxide NF</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  - 40-70 (inclusive) years in age,&#xD;
&#xD;
          -  meet 2017 McDonald criteria (Thompson 2018),&#xD;
&#xD;
          -  patients with primary or secondary progressive MS (Thompson 2018),&#xD;
&#xD;
          -  at least 2 years since progressive symptom onset,&#xD;
&#xD;
          -  evidence of clinical changes over the previous 2 years unrelated to relapses:&#xD;
             increased EDSS or 20% slowing on 25-foot walk, change of ambulatory support, cognitive&#xD;
             change documented on cognitive testing. Progression defined by patients in terms of&#xD;
             ambulation perimeter or type of support to ambulate are acceptable if aforementioned&#xD;
             physician-based measure changes are not available.&#xD;
&#xD;
          -  EDSS score 3.0 to 7.0 (inclusive),&#xD;
&#xD;
          -  can be on a stable disease-modifying treatment initiated &gt; 3 months prior to&#xD;
             screening,&#xD;
&#xD;
          -  can be on stable doses of dalfampridine initiated at least one month before screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - MS relapses in the previous 6 months&#xD;
&#xD;
          -  oral glucocorticosteroid treatment within the prior 3 months&#xD;
&#xD;
          -  patient with issues undergoing MRI scans&#xD;
&#xD;
          -  pregnancy or breastfeeding&#xD;
&#xD;
          -  women of child-bearing potential not able to utilize an effective form of&#xD;
             contraception for the duration of the study&#xD;
&#xD;
          -  history of bleeding disorders&#xD;
&#xD;
          -  active gastrointestinal ulcers&#xD;
&#xD;
          -  abnormal liver function testing (aminotransferase (AST) or alanine aminotransferase&#xD;
             (ALT) &gt;2 times upper limit of normal)&#xD;
&#xD;
          -  current treatment for active malignancy or metastatic malignancy treated in the past&#xD;
             year&#xD;
&#xD;
          -  alcohol or substance use disorder&#xD;
&#xD;
          -  allergy to NAC&#xD;
&#xD;
          -  planned surgery or move within 15 months&#xD;
&#xD;
          -  use of medications/supplements with antioxidant properties (including over-the-counter&#xD;
             NAC)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Uk Sok Shin, BA</last_name>
    <phone>(415) 321-9373</phone>
    <email>uksok.shin@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emmanuelle Waubant, MD, PhD</last_name>
    <phone>415-514-8199</phone>
    <email>emmanuelle.waubant@ucsf.edu</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 8, 2021</study_first_submitted>
  <study_first_submitted_qc>November 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Emmanuelle Waubant</investigator_full_name>
    <investigator_title>Professor, Neurology UCSF Weill Institute for Neurosciences</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

